Talazoparib

• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer Recruiting
  2023-510536-37-00 Phase II 2 countries Fundacion Oncosur
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting
  2022-502254-13-00 Phase III 1 country UZ Leuven
• EVIDENT Recruiting
  2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Master Protocol for Avelumab Continuation Study. Ended
  2023-509466-38-00 Phase III 7 countries Pfizer Inc.
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended
  2024-510809-28-00 Phase III 12 countries Pfizer Inc.
• TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-ba… Ended
  2024-514104-14-00 Phase II 1 country Hospices Civils De Lyon
• TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT… Ended
  2023-509087-20-00 Phase III 12 countries Pfizer Inc.
• “A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastati… Ended
  2023-509387-24-00 Phase II 1 country Medica Scientia Innovation Research S.L.
• FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Ended
  2024-518036-36-03 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Showing 1–11 of 11 trials